Evidence map›Paper›PMID 33979972›Full record

Trial reportZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2021

[Venetoclax with low-dose cytarabine for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: results from the Chinese cohort of a phase three randomized placebo-controlled trial].

Y Hu, J Jin, Y Zhang, J D Hu, J M Li, X D Wei, S J Gao, J H Zha, Q Jiang, J Wu and 3 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Y HuUnion Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
J JinThe First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China.
Y ZhangNanfang Hospital of Southern Medical University, Guangzhou 510515, China.
J D HuFujian Medical University Union Hospital, Fuzhou 350001, China.
J M LiRuijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
X D WeiThe Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou 450008, China.
S J GaoThe First Hospital of Jilin University, Changchun 130021,China.
J H ZhaAbbVie, Inc., Mettawa, Illinois, USA.
Q JiangAbbVie, Inc., Mettawa, Illinois, USA.
J WuAbbVie, Inc., Mettawa, Illinois, USA.
W MendesAbbVie, Inc., Mettawa, Illinois, USA.
A H WeiThe Alfred Hospital and Monash University, Melbourne, Victoria, Australia.
J X WangInstitute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CytarabineLeukemia, Myeloid, AcuteAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBridged Bicyclo Compounds, HeterocyclicChinaHumansSulfonamidesBridged Bicyclo Compounds, HeterocyclicCytarabineSulfonamidesvenetoclaxLeukemia, myeloid, acuteLow-dose cytarabineVenetoclax

Identifiers

PMID33979972
PMCPMC8120118

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.